Gilead allies with targeted drug startup Tentarix in latest research bet

San Diego-based Tentarix will receive $66 million in cash and equity from Gilead, which holds an option to acquire up to three of the company’s subsidiaries.

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks